The skin — the body's largest organ, covering approximately 1.5–2 m² — has long been viewed primarily as a physical barrier against pathogens, UV radiation, and environmental toxins. Its immune functions have traditionally been discussed in the context of local inflammatory responses [1]. Keratinocytes, the predominant cells of the epidermis, were for decades regarded mainly as architects of the skin barrier: they produce the structural proteins and cornified envelope components that confer skin's mechanical and chemical resilience. Yet a growing body of evidence suggests their role extends far beyond this — the skin behaves not as a passive shield but as an active immune command center, and keratinocytes are central to that function [2].

What was studied and how

A study published in Nature in 2026 set out to determine precisely how epidermal stress events — bacterial infection or UV irradiation — affect systemic humoral immunity, meaning the arm of the immune response responsible for antibody production [1].

To systematically dissect the underlying mechanism and test its relevance in both health and disease, the authors built a multilayered experimental system:

• Keratinocyte-specific knockout mouse models for Il6, Trpv3, Ccr6, and Ccr7 — allowing the researchers to selectively turn off individual nodes of the proposed cascade and assess the downstream impact on immune responses.
• Two mouse models of systemic lupus erythematosus (SLE) — IMQ-induced (local inflammation triggered by imiquimod) and the allogeneic BM12 transfer model (bone marrow transplantation that recapitulates systemic autoimmune inflammation) — used to examine how hyperactivation of the FPP–TRPV3 axis affects autoimmune inflammation, autoantibody production, and kidney involvement.
• Skin biopsy samples from SLE patients — providing clinical validation and allowing the authors to confirm whether the molecular patterns identified in mice are reproduced in humans.
• Intradermal immunization — used to evaluate the adjuvant potential of FPP under conditions approximating vaccination.
• Calcium imaging and electrophysiological analysis — employed to directly confirm that FPP physically binds to TRPV3 and activates the channel, triggering Ca²⁺ influx.

Molecular cascade: from keratinocyte stress to antibodies

The central finding of the study is the identification of a novel molecular pathway linking keratinocyte stress to systemic immune activation. In response to a stressful stimulus — bacterial infection or UV exposure — keratinocytes initiate the unfolded protein response (UPR), a cellular reaction to the accumulation of misfolded proteins in the endoplasmic reticulum.

UPR activates the transcription factor SREBF: released from the endoplasmic reticulum membrane where it is normally held inactive, SREBF translocates to the nucleus and switches on the mevalonate pathway — a fundamental cellular mechanism for synthesizing cholesterol, steroid hormones, and various lipid molecules. Under stress conditions, however, the pathway diverges from its usual output: instead of cholesterol, keratinocytes accumulate farnesyl pyrophosphate (FPP) — an intermediate metabolite of the same pathway that the authors describe as a "metabolic alarmin," a danger signal alerting the immune system to distress in the epidermis.

FPP acts unusually for a metabolite: it directly binds to the transmembrane channel TRPV3 (transient receptor potential vanilloid 3) — a calcium-permeable ion channel located on the keratinocyte membrane that normally responds to thermal stimuli [3]. FPP binding at two specific sites within the channel's cytoplasmic domain causes the channel to open, allowing Ca²⁺ ions to flow into the cell. Rising intracellular calcium is a universal alarm signal in cell biology: it triggers a chain of molecular events that ultimately leads keratinocytes to synthesize and release two key immune mediators — the chemokine CCL20 and the cytokine IL-6 (interleukin-6).

Each mediator plays a distinct role in the immune response. CCL20 recruits CCR6⁺ migratory dendritic cells from the skin to regional lymph nodes — a mechanism also described in the context of autoimmune processes [4]. IL-6, in turn, supports the expansion of follicular T helper (Tfh) cells and germinal center reactions.

The result of this cascade is plasma cell differentiation and high-affinity antibody production. Keratinocytes, it turns out, can translate local epidermal stress into a full systemic humoral immune response.

When the axis works — and when it fails

The authors convincingly demonstrated that the FPP–TRPV3 pathway not only exists but serves a specific protective function.

Mice with keratinocyte-specific deletion of Il6 showed a marked reduction in germinal center reactions; similar effects were observed with anti-CCL20 therapy and knockout of Ccr6 and Ccr7. Animals with keratinocyte-specific Trpv3 deletion exhibited impaired humoral protection against Group A Streptococcus (Streptococcus pyogenes)—the pathogen responsible for strep throat, erysipelas, and a range of other conditions. This confirms that the FPP–TRPV3 axis is required for normal antibody-mediated defense against infection.

The flip side of this biology is pathological hyperactivation. In both SLE mouse models, enhanced activity of the mevalonate pathway was detected in keratinocytes, correlating with elevated autoantibody production. Pharmacological inhibition of the pathway's key enzyme — HMG-CoA reductase — with simvastatin reduced FPP accumulation in inflamed skin and suppressed expression of factors that drive antibody production. This points to a potentially new rationale for statin use in SLE, a disease for which the development of targeted therapeutic approaches remains an ongoing challenge [5].

Limitations

The study was conducted primarily in mouse models; clinical data are limited to observations in patients with SLE. Certain potential mediators produced by keratinocytes under stress — including thymic stromal lymphopoietin (TSLP) — were not examined within the described pathway. Other epidermal immune populations, such as tissue-resident T cells and Langerhans cells, which may interact with the FPP–TRPV3 axis, were also outside the scope of this study.

Implications for clinical practice

The work by Ji et al. redefines the immunological status of keratinocytes: rather than passive structural elements, they emerge as active regulators of systemic humoral immunity. For practicing specialists, this opens up several important perspectives.

• Skin stress as a systemic trigger. UV radiation, infection, and chronic barrier disruption should now be considered not only as local events but as stimuli capable of initiating a systemic immune response. This is particularly relevant when managing patients with cutaneous SLE and atopic dermatitis, in which epidermal stress is central to pathogenesis.
• TRPV3 as a novel therapeutic target. Until now, this channel was known primarily as a thermosensor and contributor to itch signaling [3]. Its newly described immunoregulatory role creates opportunities for topical interventions: modulation of TRPV3 could both suppress hyperreactivity in autoimmune dermatoses and enhance immune responsiveness when it is reduced.
• Statins in dermatology — a new angle. Inhibition of the mevalonate pathway reduces FPP production and suppresses keratinocyte-derived factors that drive antibody responses [5], adding a new dimension to the well-established anti-inflammatory effects of statins and may help contextualize clinical observations in dermatological practice.
• Adjuvants for intradermal vaccination. Controlled activation of the FPP–TRPV3 axis may provide the basis for developing novel adjuvant strategies that enhance humoral responses to intradermally administered vaccines.

How these mechanisms play out across different dermatological conditions — and in which clinical contexts targeting the FPP–TRPV3 axis will prove safe and therapeutically meaningful in humans — remains to be established.

References

1. Ji Z., Gao J., Zhang S. et al. A metabolic alarmin from keratinocytes potentiates systemic humoral immunity. Nature 2026; 652: 209–219.
2. Kabashima K., Honda T., Ginhoux F., Egawa G. The immunological anatomy of the skin. Nat Rev Immunol 2019; 19: 19–30.
3. Xu H., Ramsey I.S., Kotecha S.A. et al. TRPV3 is a calcium-permeable temperature-sensitive cation channel. Nature 2002; 418: 181–186.
4. Zhang X., Chen Y., Sun G. et al. Farnesyl pyrophosphate potentiates dendritic cell migration in autoimmunity through mitochondrial remodeling. Nat Metab 2024; 6: 2118–2137.
5. Tsokos G.C. The immunology of systemic lupus erythematosus. Nat Immunol 2024; 25: 1332–1343.